Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Cash: 2015-2025

Historic Change in Cash for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$16.8 million.

  • Spyre Therapeutics' Change in Cash fell 164.19% to -$16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year increase of 67.11%. This contributed to the annual value of -$99.8 million for FY2024, which is 165.31% down from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Change in Cash is -$16.8 million, which was down 150.54% from $33.2 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Change in Cash peaked at $200.1 million during Q2 2023, and registered a low of -$182.4 million during Q2 2024.
  • Over the past 3 years, Spyre Therapeutics' median Change in Cash value was $17.8 million (recorded in 2024), while the average stood at $2.6 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Change in Cash tumbled by 11,737.94% in 2023, and later soared by 28,116.06% in 2024.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Change in Cash stood at -$9.5 million in 2021, then surged by 56.92% to -$4.1 million in 2022, then skyrocketed by 2,472.40% to $97.3 million in 2023, then tumbled by 81.66% to $17.8 million in 2024, then tumbled by 164.19% to -$16.8 million in 2025.
  • Its Change in Cash was -$16.8 million in Q3 2025, compared to $33.2 million in Q2 2025 and -$40.9 million in Q1 2025.